Bone marrow transplantation depleted of t cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: A therapeutic strategy

Transplantation

Volumn 69, Issue 7, 2000, Pages 1358-1363

  Novitzky, Nicolas ^a,b   Rubinstein, Riva ^a   Hallett, Janet M ^a   Du Toit, Cecile E ^a   Thomas, Valda L ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA ANTIGEN; LIVER ENZYME; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE;

EID: 0034655355     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200004150-00025     Document Type: Article

References (36)

1. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann Intern Med 1988; 108: 806.
2. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukaemia by marrow transplantation. Blood 1993; 82: 1954.
3. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukaemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84(6): 2036.
4. Mackinnon S, Goldman JM. Bone marrow transplantation for CML. Baillieres Clin Haematol 1987; 1: 1055.
5. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667.
6. Kernan NA, Collins NH, Cunningham I, et al. Prevention of GVHD in HLA- marrow grafts by removal of T cells with soybean agglutinin and SRBCs. Bone Marrow Transplant 1987; 2 (Suppl 1): 13.
7. Waldmann H, Hale G, Cividalli G et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; ii: 483.
8. Aschan J, Ringden O, Sundberg B, Klaesson S, Ljungman P, Lonnqvist B. Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of GVHD. Eur J Haematol 1993; 50: 269.
9. Arcese W, Goldman JM, D'Arcangelo E, et al. Outcomes for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 1993; 82: 3211.
10. Mrsic M, Horowitz MM, Atkinson K, et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269.
11. Kolb HJ, Mittermuller J, Clemm Ch, et al. Donor leukocyte transfusions for treatment of recurrent chronic myeloid leukemia in marrow transplant patients. Blood 1990; 76: 2462.
12. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 1995; 15: 591.
13. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukaemia after bone marrow transplantation: separation of grafts vs. leukaemia responses from graft vs. host disease. Blood 1995; 86: 1261.
14. Bodmer JG, Marsh SGE, Alber ED, et al. Nomenclature for factors of the HLA system, 1991. Tissue Antigens 1991; 39: 161.
15. Jacobs P, Wood L, Fullard L, Waldmann H, et al. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994; 13: 763.
16. Novitzky N, Thomas V, Hale G, Waldman H. Ex vivo depletion of T-cells from BM grafts with CAMPATH 1G in acute leukemia: graft vs. host disease and graft vs. leukemia effect. Transplantation 1999; 67: 620.
17. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft vs host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295.
18. Xu WM, Piao XH, Addy L, Jamal M, Minden MD, Messner HA. Minimal residual disease in bone marrow transplant recipients with chronic myeloid leukemia. Bone Marrow Transplant 1994; 14(2): 299.
19. Rubinstein R, Purves L R. A novel BCR-ABL rearrangement in a Philadelphia chromosome-positive chronic myelogenous leukaemia variant with thrombocythaemia. Leukaemia 1998; 12: 230.
20. Du Toit C, Novitzky N. GVL & GVHD following the infusion of a limited number of donor CD3 cells in the therapy of leukemia relapse after bone marrow transplantation. Eur J Hematol 1999; 62(1): 68.
21. Mathew P, Bozeman P, Krance R A, et al. Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 13(2): 221.
22. Rapoport AP, DiPersio JF, Martin BA, et al. Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 years. Bone Marrow Transplant 1995; 15(4): 523.
23. Slavin S, Nagler A, Naparstek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic disease. Blood 1998; 91: 756.
24. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft- versus-leukaemia without myeloablative therapy. Blood 1997; 89: 4531.
25. Enright H, Davies SM, De For T, et al. Relapse after non-T-cell depleted allogeneic bone marrow transplantation for chronic myelogenous leukaemia: early transplantation, use of an unrelated donor and chronic grafts vs. host disease are protective. Blood 1996; 88: 714.
26. Ten Bosch GJA, Joosten AM, Kessler JH, et al. Recognition of BCR/ABL positive leukemic blasts by human CD 4+ T cells elicited by primary in vitro immunization with BCR-ABL breakpoint peptide. Blood 1998; 88: 3522.
27. Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T cell responses against chimeric p210 BCR-ABL protein in patients with chronic myeloid leukemia. J Clin Invest 1988; 10: 2290.
28. Jing YZ, Cullis JO, Kanfer EJ, Goldman JM, and Barrett AJ. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1993; 11: 133.
29. Bacigalupo A, Soracco M, Vassallo F, et al. Donor lymphocyte infusion (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 927.
30. Clark RE, and Pender N. Transplantation of T-lymphocyte depleted marrow with an addback of T cells. Hematol Oncol 1995; 13: 219.
31. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of 2 parts). N Engl J Med 1975; 292: 895.
32. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671.
33. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041.
34. Van Rhee F, Szydlo RM, Hermans J, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20(7): 553.
35. Gratwohl A, Hermans J, Apperley J, et al. Acute graft vs host disease: grade and outcome in patients with chronic myelogenous leukaemia. Blood 1995; 86: 813.
36. Schmitz N, Bacigalupo A, Labopin, et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors: European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 95(4): 715.